|
gptkbp:instanceOf
|
gptkb:drug
triptan
|
|
gptkbp:approvalYear
|
1998
|
|
gptkbp:ATCCode
|
N02CC04
|
|
gptkbp:bioavailability
|
40-45%
|
|
gptkbp:brand
|
gptkb:Maxalt
|
|
gptkbp:CASNumber
|
145202-66-0
|
|
gptkbp:chemicalClass
|
indole derivative
|
|
gptkbp:contraindication
|
ischemic heart disease
uncontrolled hypertension
history of stroke
|
|
gptkbp:discoveredBy
|
gptkb:Merck_&_Co.
|
|
gptkbp:eliminationHalfLife
|
2-3 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
gptkb:tablet
orally disintegrating tablet
|
|
gptkbp:hasMolecularFormula
|
C15H19N5O2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
rizatriptan
|
|
gptkbp:KEGGID
|
gptkb:D08402
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
5-HT1B/1D receptor agonist
|
|
gptkbp:MedlinePlusID
|
a698015
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
14%
|
|
gptkbp:PubChem_CID
|
5073
CHEMBL1201
DB00953
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
fatigue
drowsiness
dry mouth
|
|
gptkbp:synonym
|
MK-462
|
|
gptkbp:UNII
|
L6O9Y9Y75Z
|
|
gptkbp:usedFor
|
migraine
|
|
gptkbp:bfsParent
|
gptkb:Maxalt
|
|
gptkbp:bfsLayer
|
6
|